Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-12-09 EST			5-day change	1st Jan Change
770.00 ^DKK	+0.06%		+5.91%	+106.32%

12-09	Swedbank Robur Småbolagsfond Norden decreased 2.03 percent in November - added Netcompany to the portfolio	FW
11-21	Zealand Pharma A/S Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 09:30 AM

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Zealand Pharma A/S

Swedbank Robur Småbolagsfond Norden decreased 2.03 percent in November - added Netcompany to the portfolio	12-09	FW
Zealand Pharma A/S Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 09:30 AM	11-21
KBC Securities Initiates Zealand Pharma at Buy	11-20	MT
Zealand Pharma rallies after JP Morgan initiates Overweight rating	11-08	FW
Danske Bank raises Zealand Pharma to 'Keep' (Sell), target price 825 Danish kroner - BN	11-08	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,095 (1,106), reiterates Buy - BN	11-08	FW
JP Morgan initiates coverage of Zealand Pharma with Overweight and target price of DKK 1,100 - BN	11-08	FW
Zealand Pharma A/S, Q3 2024 Earnings Call, Nov 07, 2024	11-07
Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-07	CI
Zealand Pharma reports promising results for weight loss drug - BN	11-06	FW
Novo Nordisk share price falls after Viking Therapeutics pill update	11-04	FW
Today's stock recommendations at a glance	10-15	FW
Bank of America initiates coverage of Zealand Pharma with Buy and target price of DKK 1,100 - BN	10-15	FW
Zealand Pharma falls after getting CRL from FDA	10-09	FW
Zealand Pharma Gets US FDA's Complete Response Letter for Hypoglycemia Drug	10-09	MT
Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism	10-08	CI
Zealand Pharma Gets FDA Complete Response Letter for Hypoglycemia New Drug Application	10-08	DJ
Boehringer Secures Breakthrough Designation for MASH, Fibrosis Treatment	10-08	MT
Zealand, Boehringer win FDA breakthrough status to treat fatty liver	10-08	RE
Deutsche Bank Begins Zealand Pharma Coverage at Hold	10-02	MT
Today's stock recommendations at a glance	10-02	FW
Deutsche Bank initiates coverage of Zealand Pharma with "Hold" and target price of DKK 815	10-02	FW
Certain Ordinary Shares of Zealand Pharma A/S are subject to a Lock-Up Agreement Ending on 24-SEP-2024.	09-23	CI
Zealand Pharma A/S(CPSE:ZEAL) added to S&P International 700	09-22	CI
Zealand Pharma A/S(CPSE:ZEAL) added to S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)	09-22	CI

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

298

Sector

Biotechnology & Medical Research

Calendar

2025-02-20 - Q4 2024 Earnings Release

More about the company